NCT04497584View on ClinicalTrials.gov

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions
Advanced Squamous Non Small Cell Lung Cancer
Interventions
DRUG

Afatinib + Prednisone

Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER